Nuvalent drops as Q1 results and FDA program updates hit tape
Nuvalent released first-quarter 2026 results and corporate updates on May 7, 2026, alongside an 8-K filing. The update highlighted an NDA submission for neladalkib and ongoing FDA review of zidesamtinib with a September 18, 2026 PDUFA date.
1) What happened today
Nuvalent filed an 8-K and issued a May 7, 2026 press release reporting first-quarter 2026 financial results and providing corporate updates, creating a same-day information catalyst for the stock. The release reiterated pipeline milestones and described operational updates (including leadership promotions and upcoming conference appearances).
2) Pipeline/regulatory highlights in the release
The release stated that the NDA for zidesamtinib is under FDA review with a PDUFA target action date of September 18, 2026, and that the company submitted an NDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC. It also noted plans for a potential label-expansion submission for zidesamtinib in the second half of 2026 and referenced planned ASCO 2026 presentations.
3) Financial items investors may have reacted to
Nuvalent reported a Q1 2026 net loss of $109.3 million and reported cash, cash equivalents, and marketable securities of about $1.3 billion as of March 31, 2026, with an expectation that existing funds can support operations into 2029. R&D expense was reported at $83.6 million and G&A at $35.8 million for the quarter.